{"extracted_data":{"study_name":"Study from Belaroussi 2023.pdf","file_name":"Belaroussi 2023.pdf","metadata":{"version":"1.0","description":"RWE Studies Annotations for Extraction Task","created_at":"2025-03-22T18:16"},"raw_data":{"treatment_regimens":["chemotherapy","immunotherapy","chemotherapy-ICI combination","pembrolizumab monotherapy","pembrolizumab plus chemotherapy"],"countries":["France"],"populations":[{"stage_histology":"Stage IV NSCLC","pdl1_status":"≥50%","n":5294}],"results":{"treatment_specific_results":{"immunotherapy":{"tnt":"7.4 months","median_os":"16.4 months","median_rw_pfs":"5.0 months"},"chemotherapy":{"median_rw_pfs":"4.0 months","tnt":"4.3 months","median_os":"11.6 months"}},"group_difference":"HR = 0.59; 95%CI [0.42–0.83], p < 0.01","median_os":"11.8 months","median_rw_pfs":"4.0 months","os_12_month":"60.8%"}}},"status":"success","_timestamp":1.742663799200288e+09,"_runtime":7.99355,"_wandb":{"runtime":8},"_step":0,"study_name":"Study from Belaroussi 2023.pdf"}